Xipere Injection, Suspension
Product Images NDC 24208-040

Product Visual Gallery

This gallery contains 21 technical images submitted to the FDA as part of the official labeling for Xipere (NDC 24208-040). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bausch & Lomb Incorporated, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Components For Administration (Xipere 01)

An instructional illustration showing components of Xipere ophthalmic injection, suspension. It includes a vial labeled with product information, a syringe with vial adapter, and two dose applicator tips labeled with letters A through D to identify each part of the administration system.*

FDA Label Image

Step 1 (Xipere 02)

Xipere 40 mg/mL triamcinolone acetonide ophthalmic injection, suspension packaging features a white carton and a blister pack containing a single vial. The label indicates the product is manufactured by Bausch & Lomb Incorporated with visible NDC 24208-040.*

FDA Label Image

Step 2 (Xipere 03)

An illustration showing a close-up of a device used for an ophthalmic procedure, featuring a platform with a control panel and an elongated arm. The image appears to depict equipment related to eye injections or treatments.*

FDA Label Image

Step 3 (Xipere 04)

An instructional illustration showing how to open or prepare a vial or container, depicting a hand pulling back or lifting a cap or lid from a small container. The image is monochrome and line-drawn.*

FDA Label Image

Step 4 (Xipere 05)

An instructional illustration showing a hand peeling back the foil seal of a sterile medication tray containing a vial and syringe. The image demonstrates the initial step in accessing the ophthalmic injection suspension from its protective packaging.*

FDA Label Image

Step 5 (Xipere 06)

The illustration shows a three-step instructional diagram for opening a surgical or medical container. Step one depicts lifting the top cover open. Step two shows pressing or shaking the top with sound waves indicating an action. Step three reveals the contents inside the container, which include a prefilled syringe and associated medical components.*

FDA Label Image

Step 6 (Xipere 07)

Instructional diagram showing steps to prepare Xipere 40 mg/mL ophthalmic injection suspension. It depicts shaking the vial for 10 seconds, holding the vial upright, removing the cap by pulling upwards, and an image of the vial labeled with the product name and strength.*

FDA Label Image

Step 7 (Xipere 08)

An instructional drawing showing a hand removing a small vial and a syringe from a medical tray or container. The illustration likely demonstrates preparation steps for administering an ophthalmic injection, specifically the Xipere triamcinolone acetonide injection suspension.*

FDA Label Image

Step 8 (Xipere 09)

An instructional illustration showing a hand pressing the plunger of an ophthalmic injection suspension vial labeled Xipere, 40 mg/mL triamcinolone acetonide by Bausch & Lomb Incorporated. The arrow indicates downward pressure on the plunger to draw or inject the liquid.*

FDA Label Image

Step 9 (Xipere 10)

An instructional illustration showing two steps for handling an Xipere ophthalmic injection suspension syringe. Step i depicts hands pulling the syringe plunger up and down. Step ii shows a close-up of the syringe with graduated markings on the barrel.*

FDA Label Image

Step 10 (Xipere 11)

An instructional illustration demonstrating the method of preparing the Xipere ophthalmic injection suspension. It shows a hand holding the syringe vial and another hand holding the suspension vial, with arrows indicating the removal of the cap from the suspension vial and attachment to the syringe vial.*

FDA Label Image

Step 11 (Xipere 12)

An instructional illustration showing a hand twisting the cap of a vial to reveal or access the stopper. The image is likely a step in preparing the ophthalmic injection suspension Xipere (triamcinolone acetonide) 40 mg/mL by Bausch & Lomb Incorporated.*

FDA Label Image

Step 12 (Xipere 13)

An illustration showing a syringe with a capped needle and a plunger. An upward arrow next to the syringe indicates the direction of plunger movement, likely demonstrating how to draw or inject the medication.*

FDA Label Image

Step 13 (Xipere 14)

An instructional diagram showing the administration of an ophthalmic injection. It depicts a syringe positioned approximately 4 to 4.5 millimeters from the eye, illustrating the proper injection method for an eye medication.*

FDA Label Image

Step 14 (Xipere 15)

An instructional illustration showing an ophthalmic injection procedure. The image depicts a syringe positioned to administer an injection into the eye, indicating the intended route of administration for the medication.*

FDA Label Image

Step 15 (Xipere 16)

An illustration shows a dropper dispensing a liquid drop into an eye, demonstrating ophthalmic administration of a medication.*

FDA Label Image

Step 16 (Xipere 17)

An instructional illustration demonstrating the technique for administering an ophthalmic injection suspension. The top image shows a hand holding a syringe near an eye, indicating the method of injection. The bottom image depicts a close-up of a syringe tip with a protective cover being removed by pulling it upward.*

FDA Label Image

Chemical Structure (Xipere 18)

Chemical structure of triamcinolone acetonide, the active ingredient in Xipere 40 mg/mL ophthalmic injection suspension by Bausch & Lomb Incorporated.*

FDA Label Image

Figure 1 (Xipere 19)

A line graph comparing the mean change from baseline in BCVA (letters) over 24 weeks between two groups: Xipere (N=96) and Control (N=64). The Xipere group shows a greater increase in BCVA letters over time compared to the Control group, with data points plotted at multiple weeks from 0 to 24.*

FDA Label Image

Figure 2 (Xipere 20)

A line graph comparing mean change from baseline in central subfield retinal thickness (microns) over 24 weeks between two groups: Xipere (N=94) and Control (N=61). The Xipere group shows a substantial decrease in retinal thickness throughout the period, while the Control group exhibits minimal change.*

FDA Label Image

Carton (Xipere 23)

Packaging label for Xipere (triamcinolone acetonide injectable suspension) 40 mg/mL by Bausch & Lomb. The label indicates the product is for supracochoroidal use and includes a carton containing one single-dose glass vial, a microinjector syringe with vial adapter, two needles (30-G x 900-µm and 30-G x 1100-µm), and a package insert. The label features preparation instructions illustrated with step-by-step images and storage information.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.